Aster DM Healthcare Reports Strong Q2 FY26 Performance, Kerala Recovery, and Significant Merger Progress
Aster DM Healthcare reported strong Q2 FY26 results, 10% revenue growth, and margin expansion. Kerala recovered. Merger with Quality Care India Limited is progressing, creating a combined entity of over 10,360 beds.
The announcement details robust Q2 FY26 financial results, including strong revenue growth and margin expansion, indicating operational efficiency. The successful recovery of the Kerala cluster, a key market, is a significant positive. Furthermore, the substantial progress in the merger with Quality Care India Limited, which will create a combined entity with over 10,360 beds, has a high impact on the company's scale, market position, and future growth trajectory.
The company reported strong financial performance with significant revenue growth, margin expansion, and a notable recovery in the key Kerala cluster. Additionally, the merger with Quality Care India Limited is progressing well, promising substantial future growth and market leadership, all contributing to a positive outlook.
* Aster DM Healthcare announced the release of the transcript for its Q2 FY26 earnings conference call, held on November 7, 2025, covering the quarter and half year ended September 30, 2025. * For Q2 FY26, the company's consolidated revenue grew 10% year-on-year to ₹1,197 crore. Operating EBITDA increased 13% year-on-year to ₹263 crore, achieving a 22.0% margin. Normalised PAT (Post NCI) rose 14% year-on-year to ₹110 crore. * The Average Revenue Per Patient (ARPP) for inpatients increased by 10% year-on-year, driven by a richer specialty mix, with Oncology revenue growing 26% year-on-year. * Total patient volume increased 15% quarter-on-quarter, with inpatient volumes up 12% and outpatient volumes up 15%. Occupancy improved to 64% in Q2 FY26 from 59% in Q1 FY26. * The Medical Value Travel (MVT) segment showed strong momentum, growing 60% quarter-on-quarter and 26% year-on-year. * The Kerala cluster delivered its highest-ever quarterly revenue of ₹620 crore, a 24% increase over Q4 FY25, with inpatient volumes up 13% sequentially and MVT growing 67% quarter-on-quarter and 49% year-on-year. Operating EBITDA margins for Kerala expanded to 26.8% from 22.3% in Q4 FY25. * On a proforma basis, the combined entity (Aster + Quality Care India Limited) delivered healthy performance, with revenues organically growing 13% year-on-year to ₹2,390 crore, operating EBITDA growing 17% to ₹550 crore, and Normalised PAT growing 22% to ₹258 crore, resulting in a 23% operating EBITDA margin. * The company added over 200 beds in the past year, bringing total capacity to 5,199 beds as of September 30, 2025. A new 264-bed hospital in Kasaragod was commissioned on October 2, 2025. Plans are in place to add another 2,300+ beds, taking total capacity beyond 7,800 beds. * Aster acquired an additional 13% stake in Aster Ramesh Hospitals, increasing its stake to over 70%. * Progress on the merger with Quality Care India Limited (QCIL) continues, with no-objection letters received from BSE and NSE, and approval from the Competition Commission of India (CCI). The company will now approach the NCLT for final approval. Upon completion, the merged platform will have 38 hospitals across 27 cities with over 10,360 beds. * Ms. Alisha Moopen, Deputy Managing Director, highlighted the Indian economy's resilience and the hospital sector's growth, driven by higher insurance penetration and expanding medical infrastructure. She emphasized the company's consistent revenue growth over 20 consecutive quarters and the synergy potential from the merger. * Quality Care India Limited (QCIL) reported strong Q2 FY26 performance, with revenue growing 15.1% year-on-year to ₹1,193 crore and post-Ind AS EBITDA rising 21.6% year-on-year to ₹287 crore, with a 24.1% margin. QCIL plans to invest around ₹2,000 crore to add over 1,700 beds in the next 3-4 years.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.